Pfizer (PFE) and Valneva (VALN) Report Positive Pediatric and Adolescent Phase 2 Booster Results Sep 7, 2023 05:20AM
Pfizer (PFE) and Valneva (VALN) Issue Update on Phase 3 Clinical Trial of VLA15 Feb 17, 2023 05:49AM
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15 Feb 17, 2023 01:00AM
Valneva and Pfizer Report Six-Month Antibody Persistence Data in Children and Adults for Lyme Disease Vaccine Candidate Dec 1, 2022 01:00AM
Pfizer (PFE) and Valneva (VALN) Initiate Phase 3 Study of VLA15 Aug 8, 2022 04:47PM


Aug 8, 2022 04:45PM Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Aug 8, 2022 04:45PM Pfizer and Valneva Initiate Phase 3 Study of Lyme Disease Vaccine Candidate VLA15
Jun 23, 2022 11:45AM Valneva and Pfizer Announce Closing of Equity Investment
Jun 21, 2022 06:11AM Valneva SE (VALN), Pfizer (PFE) Enter Equity Subscription Agreement and Update Terms of Collaboration
Jun 20, 2022 01:00AM Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Jun 20, 2022 01:00AM Valneva and Pfizer Enter into an Equity Subscription Agreement and Update Terms of Collaboration Agreement for Lyme Disease Vaccine Candidate VLA15
Apr 26, 2022 06:45AM Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Apr 26, 2022 05:41AM Valneva SE (VALN) and Pfizer (PFE) Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Apr 26, 2022 01:00AM Valneva and Pfizer Report Positive Phase 2 Pediatric Data for Lyme Disease Vaccine Candidate
Mar 29, 2022 08:00AM ShouTi Appoints Sharon Tetlow to Board of Directors
Mar 15, 2022 07:01AM Altimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
Feb 21, 2022 01:00AM Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development
Feb 4, 2022 05:27AM Pfizer (PFE) and Valneva (VALN) Report Additional Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Feb 4, 2022 01:00AM Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate
Nov 9, 2021 04:01PM Altimmune Announces Third Quarter 2021 Financial Results and Provides a Corporate Update
Sep 28, 2021 01:00AM Valneva and Pfizer Report Further Positive Phase 2 Results, Including Booster Response, for Lyme Disease Vaccine Candidate
Jul 19, 2021 01:00AM Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate
May 11, 2021 04:00AM Citi Appointed as Depositary Bank for Valneva SE’s ADR Programme